Insights from Digital Pharma Leaders
Refine search
Biotechnology
US pharma giant Pfizer has signed a license agreement with San Francisco-based Chai Discovery, giving its scientists access to the AI company’s drug discovery platform for biologics research. 5 June 2026
Pharmaceutical
US biopharma Alnylam Pharmaceuticals has signed a strategic AI collaboration with Inceptive Nucleics, as it looks to speed up the discovery of RNA interference therapies and broaden its pipeline under its Alnylam 2030 strategy. 4 June 2026
Biotechnology
Danish CNS specialist Lundbeck (and Cradle, a Dutch AI platform for protein engineering, today announced a partnership to help Lundbeck discover and optimize biotherapeutics that ultimately can improve patient outcomes. 3 June 2026
Pharmaceutical
German techbio company Lucera has launched with ambitions to improve decision-making across pharmaceutical research and development using artificial intelligence and a curated biomedical knowledge base. 2 June 2026
Biotechnology
British techbio Genomics has launched Mystra AI, a human genetics-based artificial intelligence platform designed to help drugmakers identify and validate better targets for drug discovery. 2 June 2026
Biotechnology
Genesis Molecular AI and Incyte announced a new kind of deal, with Incyte’s proprietary experimental data powering large-scale training of Genesis’ drug discovery platform. It is backed with $120 million upfront and approximately $5 billion for up to 20 potential targets. 21 May 2026
Pharmaceutical
US pharma major Bristol Myers Squibb has signed a broad artificial intelligence partnership with Anthropic, deploying the tech company’s Claude platform across research, clinical development, manufacturing, commercial operations and corporate functions. 21 May 2026
Pharmaceutical
Incyte and Edison Scientific have announced a strategic collaboration to employ Kosmos, Edison’s AI scientist, for the US biopharma’s discovery and development work. 20 May 2026
Pharmaceutical
Chicago, USA-based artificial intelligence company Tempus AI announced a new initiative with US pharma major Bristol Myers Squibb. 15 May 2026
Pharmaceutical
US AI leader Anthropic is expanding further into healthcare and drug development through a new four-year partnership with the Gates Foundation focused on vaccines, disease modeling and health-system operations in lower-income countries. 15 May 2026
Biotechnology
UK-based Isomorphic Labs, the AI-driven drug discovery company spun out of Google DeepMind, has raised $2.1 billion in a Series B financing round. 13 May 2026
Biotechnology
Privately-held Boston, USA, firm Cellular Intelligence has acquired global rights to Novo Nordisk's cell therapy program for Parkinson's disease. 12 May 2026
Pharmaceutical
British pharma major AstraZeneca is expanding its oncology-focused artificial intelligence collaboration with US biotech Immunai in a deal that could bring the smaller company up to $37.5 million over 2026-2027. 8 May 2026
Pharmaceutical
Ahead of a London event on May 12 on how AI is rapidly reshaping how healthcare information is discovered, interpreted and shared, this week's Expert View comes from panellist Sophie Randall, Director of the Patient Information Forum, the UK membership organization for people working in health information and support. 6 May 2026
Biotechnology
Profluent, the frontier AI company pioneering large-scale foundation models for protein design, today announced a multi-program strategic research collaboration with Eli Lilly to develop and commercialize custom site-specific recombinases to address diseases with severe unmet needs. 28 April 2026
Biotechnology
Belgian drugmaker UCB and the University of Southampton have announced a joint three-year project that they have dubbed the Digital Antibody Research Collaboration (DARC). 27 April 2026
Pharmaceutical
Merck & Co and Google Cloud have announced a landmark partnership to enhance the US pharma giant’s digital backbone as an AI-enabled enterprise. 23 April 2026
Biotechnology
This week on The Pharma Letter Podcast, we’re joined by Kenneth Mulvany, founder and executive chair of BenevolentAI: one of the UK’s earliest and most high-profile attempts to apply machine learning to drug discovery. 23 April 2026
Biotechnology
US biotech major Amgen has announced the retirement of David Reese, executive vice president and chief technology officer, effective June 30. 23 April 2026
Biotechnology
US biotech Elephas Biosciences has entered a research collaboration with artificial intelligence firm Mithrl, aiming to combine real-time tumor profiling with automated data analysis to better understand responses to immunotherapy. 17 April 2026
Biotechnology
US pharma giant Pfizer has signed a license agreement with San Francisco-based Chai Discovery, giving its scientists access to the AI company’s drug discovery platform for biologics research. 5 June 2026
Pharmaceutical
US biopharma Alnylam Pharmaceuticals has signed a strategic AI collaboration with Inceptive Nucleics, as it looks to speed up the discovery of RNA interference therapies and broaden its pipeline under its Alnylam 2030 strategy. 4 June 2026
Biotechnology
Danish CNS specialist Lundbeck (and Cradle, a Dutch AI platform for protein engineering, today announced a partnership to help Lundbeck discover and optimize biotherapeutics that ultimately can improve patient outcomes. 3 June 2026
Pharmaceutical
German techbio company Lucera has launched with ambitions to improve decision-making across pharmaceutical research and development using artificial intelligence and a curated biomedical knowledge base. 2 June 2026
Biotechnology
British techbio Genomics has launched Mystra AI, a human genetics-based artificial intelligence platform designed to help drugmakers identify and validate better targets for drug discovery. 2 June 2026
Biotechnology
Genesis Molecular AI and Incyte announced a new kind of deal, with Incyte’s proprietary experimental data powering large-scale training of Genesis’ drug discovery platform. It is backed with $120 million upfront and approximately $5 billion for up to 20 potential targets. 21 May 2026
Pharmaceutical
US pharma major Bristol Myers Squibb has signed a broad artificial intelligence partnership with Anthropic, deploying the tech company’s Claude platform across research, clinical development, manufacturing, commercial operations and corporate functions. 21 May 2026
Pharmaceutical
Incyte and Edison Scientific have announced a strategic collaboration to employ Kosmos, Edison’s AI scientist, for the US biopharma’s discovery and development work. 20 May 2026
Pharmaceutical
Chicago, USA-based artificial intelligence company Tempus AI announced a new initiative with US pharma major Bristol Myers Squibb. 15 May 2026
Pharmaceutical
US AI leader Anthropic is expanding further into healthcare and drug development through a new four-year partnership with the Gates Foundation focused on vaccines, disease modeling and health-system operations in lower-income countries. 15 May 2026
Biotechnology
UK-based Isomorphic Labs, the AI-driven drug discovery company spun out of Google DeepMind, has raised $2.1 billion in a Series B financing round. 13 May 2026
Biotechnology
Privately-held Boston, USA, firm Cellular Intelligence has acquired global rights to Novo Nordisk's cell therapy program for Parkinson's disease. 12 May 2026
Pharmaceutical
British pharma major AstraZeneca is expanding its oncology-focused artificial intelligence collaboration with US biotech Immunai in a deal that could bring the smaller company up to $37.5 million over 2026-2027. 8 May 2026
Pharmaceutical
Ahead of a London event on May 12 on how AI is rapidly reshaping how healthcare information is discovered, interpreted and shared, this week's Expert View comes from panellist Sophie Randall, Director of the Patient Information Forum, the UK membership organization for people working in health information and support. 6 May 2026
Biotechnology
Profluent, the frontier AI company pioneering large-scale foundation models for protein design, today announced a multi-program strategic research collaboration with Eli Lilly to develop and commercialize custom site-specific recombinases to address diseases with severe unmet needs. 28 April 2026
Biotechnology
Belgian drugmaker UCB and the University of Southampton have announced a joint three-year project that they have dubbed the Digital Antibody Research Collaboration (DARC). 27 April 2026
Pharmaceutical
Merck & Co and Google Cloud have announced a landmark partnership to enhance the US pharma giant’s digital backbone as an AI-enabled enterprise. 23 April 2026
Biotechnology
This week on The Pharma Letter Podcast, we’re joined by Kenneth Mulvany, founder and executive chair of BenevolentAI: one of the UK’s earliest and most high-profile attempts to apply machine learning to drug discovery. 23 April 2026
Biotechnology
US biotech major Amgen has announced the retirement of David Reese, executive vice president and chief technology officer, effective June 30. 23 April 2026
Biotechnology
US biotech Elephas Biosciences has entered a research collaboration with artificial intelligence firm Mithrl, aiming to combine real-time tumor profiling with automated data analysis to better understand responses to immunotherapy. 17 April 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A clinical-stage biotechnology company developing disease-modifying treatments for neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS) and broader neurodegenerative biology. Neurizon aims to advance its lead small-molecule candidate into pivotal clinical testing and position it for regulatory evaluation and eventual patient access.
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze